CTX310 for Refractory Dyslipidemias
This study is testing a new treatment called CTX310 for people with dyslipidemias (high cholesterol and triglycerides) that haven't improved with other treatments. CTX310 uses a special technology called CRISPR to target a gene involved in how your body handles fats. The main goal of this study is to see how safe CTX310 is for you, and if you can tolerate it, over a period of up to 12 months after receiving the treatment. You might be able to join if you are between 18 and 75 years old and have specific levels of high triglycerides or cholesterol. This study is currently enrolling participants.
- Study design
- This is a Phase 1, single-arm, open-label study, meaning all 90 participants will receive CTX310, and both you and the study team will know which treatment you are getting.
- What's involved
- You will receive CTX310 through an intravenous (IV) infusion. The study will monitor your safety for up to 12 months after this infusion.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for up to 12 months after receiving the CTX310 infusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
At a glance
Conditions
Where it's being run
19 sites across 8 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatmentsFrom CTX310 infusion up to 12 months
Incidence of dose-limiting toxicities and frequency of adverse events